Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.4B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetically defined diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth will provide insights into the demand for Cogent's products and overall business momentum.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetically defined diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted slightly negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding product pipelines.

Expectations

Wall Street Expectations

Overall expectations for Cogent's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance.

Bull Case

If Cogent can demonstrate significant progress in its clinical trials and show improved financial metrics, investors may respond positively.

Bear Case

Conversely, if the company fails to meet expectations again, it could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the company's recent history of missing EPS estimates, this number will be crucial for investor sentiment.

What updates can management provide on the progress of clinical trials?

Progress in clinical trials is vital for future revenue growth and will significantly impact the stock's performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cogent's pipeline advancements to drive future revenue, despite recent misses.

Supporting Evidence

The company's focus on targeted therapies could yield breakthroughs that aren't reflected in current estimates.

Options pricing suggests a larger move than historical averages, indicating potential volatility that could favor a rebound.

Key Risk

If clinical trial updates show significant progress, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Cogent's ability to improve its financial performance and clinical trial outcomes.

Bull Confirmed If

A narrower EPS loss of -$0.55 or better would confirm a bullish outlook.

Bear Confirmed If

An EPS loss greater than -$0.64 would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of over 10%, indicating heightened uncertainty around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience minimal movement.

Miss

A miss on EPS could lead to a decline, with historical averages suggesting a drop of around +3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for key therapies.
2Any changes in guidance regarding future revenue expectations.
3Details on operational efficiency improvements.
4Management's outlook on market conditions and competitive landscape.
5Insights into potential partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

RecapView

Nov1

CNAReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetically defined diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth will provide insights into the demand for Cogent's products and overall business momentum.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted slightly negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding product pipelines.

Expectations

Wall Street Expectations

Overall expectations for Cogent's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance.

Bull Case

If Cogent can demonstrate significant progress in its clinical trials and show improved financial metrics, investors may respond positively.

Bear Case

Conversely, if the company fails to meet expectations again, it could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the company's recent history of missing EPS estimates, this number will be crucial for investor sentiment.

What updates can management provide on the progress of clinical trials?

Progress in clinical trials is vital for future revenue growth and will significantly impact the stock's performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cogent's pipeline advancements to drive future revenue, despite recent misses.

Supporting Evidence

The company's focus on targeted therapies could yield breakthroughs that aren't reflected in current estimates.

Options pricing suggests a larger move than historical averages, indicating potential volatility that could favor a rebound.

Key Risk

If clinical trial updates show significant progress, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Cogent's ability to improve its financial performance and clinical trial outcomes.

Bull Confirmed If

A narrower EPS loss of -$0.55 or better would confirm a bullish outlook.

Bear Confirmed If

An EPS loss greater than -$0.64 would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of over 10%, indicating heightened uncertainty around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience minimal movement.

Miss

A miss on EPS could lead to a decline, with historical averages suggesting a drop of around +3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for key therapies.
2Any changes in guidance regarding future revenue expectations.
3Details on operational efficiency improvements.
4Management's outlook on market conditions and competitive landscape.
5Insights into potential partnerships or collaborations.